Valuation and Targets, page-342

Of course i respect @Mozzarc, and his contributions to PAR threads. I agree with you and have previously posted that i think the best path is a deal with BigPharma.
I was making a different point that taking only TGA there is considerable uplift, with the (unstated) implication that would set the scene for a deal.
I am rather puzzled that PAR haven't emphasized TGA as the priority now they know where they stand with FDA..
@Mozzarc has pointed out that getting the TGA go-ahead is a one shot opportunity and PAR need to get their application 100% right.
I am beginning to think they need to step back and rethink their priorities which should be
IMO
1. Establish market value with revenue.
2. Recognize delay is inevitable in trialing while COVID-19 is still around
3. Focus on TGA
4. Have a pre-trial for US, get the trial process right, including all steps -- WOMAC etc
5. Asses their management of that
6. Do the FDA trial.